David Eric
Insider transactions at 1 company
This page shows all SEC Form 4 filings attributed to David Eric. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| VIVS | CSO & EVP Pre-Clinical Dev | Tax Withholding | 5,625 | $1.47 | $8,269 | Nov 16, 2017 |
| VIVS | CSO & EVP Pre-Clinical Dev | Tax Withholding | 8,469 | $2.06 | $17,446 | Aug 16, 2017 |
| VIVS | CSO & EVP Pre-Clinical Dev | Award / Grant | 190,000 | — | — | Jun 27, 2017 |
| VIVS | CSO & EVP Pre-Clinical Dev | Tax Withholding | 1,263 | $2.86 | $3,612 | May 16, 2017 |
| VIVS | CSO & EVP Pre-Clinical Dev | Tax Withholding | 1,390 | $2.95 | $4,101 | Feb 16, 2017 |
| VIVS | CSO & EVP Pre-Clinical Dev | Tax Withholding | 1,745 | $3.26 | $5,689 | Nov 16, 2016 |
| VIVS | CSO & EVP Pre-Clinical Dev | Tax Withholding | 1,205 | $4.00 | $4,820 | Aug 19, 2016 |
| VIVS | CSO & EVP Pre-Clinical Dev | Sale | 20,000 | $4.55 | $91,000 | Aug 5, 2016 |
| VIVS | CSO & EVP Pre-Clinical Dev | Award / Grant | 50,000 | — | — | Jul 11, 2016 |
| VIVS | CSO & EVP Pre-Clinical Dev | Gift | 5,000 | — | — | Mar 30, 2016 |
| VIVS | Chief Strategy Officer | Sale | 16,300 | $7.56 | $123,228 | Dec 29, 2014 |
| VIVS | Chief Strategy Officer | Sale | 30,000 | $7.30 | $219,000 | Sep 12, 2014 |
| VIVS | Chief Strategy Officer | Sale | 16,470 | $10.39 | $171,123 | Nov 13, 2013 |
| VIVS | Chief Strategy Officer | X | 20,000 | $1.00 | $20,000 | Oct 10, 2013 |
| VIVS | Chief Strategy Officer | Sale | 63,000 | $5.86 | $369,180 | Oct 7, 2013 |